Skip To Main Content
Marina Baretti on Muck Rack

Marina Baretti

As seen in: Nature, MDPI, Cell Press, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marina

Contact Marina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial

|
By Hejia Wang, Amanda L Huff, S. Haldar, Maureen Berg, Christopher Thoburn, Thatcher Heumann, Robert A. Anders, Benjamin Barrett, Katherine M. Bever, Michael Pishvaian, Valerie Lee, Dung T Le, Eric Christenson Verified, Marina Baretti, Mark Yarchoan, Daniel A. Laheru, Amy Thomas, Jennifer N. Durham, Jiayun Lu, Hao Wang, Elizabeth Jaffee, Nilofer S. Azad, Neeha Zaidi, Julie M. Nauroth
| Nature Verified
Abstract Immune checkpoint inhibitors (ICIs) have limited activity in mismatch repair proficient or microsatellite stable (MMRp/MSS) colorectal cancer (CRC). KRAS mutations, present in approximately 40% of these cancers, can generate neoantigens that are targets for therapeutic vaccines.
Open in Who Shared Issue with article?

Relationship of Hepatocellular Carcinoma Stage and Hepatic Function to Health-Related Quality of Life: A Single Center Analysis

|
By Amol Gupta, Won Jin Ho, Marina Baretti, Jane Zorzi
| MDPI
1. Introduction Primary liver cancer is the sixth leading cancer type and the fourth leading cause of cancer-related mortality worldwide. In 2020, 906,000 new cases were reported, with 830,000 deaths [1]. Hepatocellular carcinoma (HCC) accounts for approximately 85% of cases of primary liver cancer and is projected to be the third leading cause of cancer-related mortality by 2030 [2].
Open in Who Shared Issue with article?

Expanding the immunotherapy roadmap for hepatocellular carcinoma

|
By Marina Baretti, Amy Kim, Robert A. Anders
| Cell Press Verified
Summary In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.
Open in Who Shared Issue with article?
See all 4 licensed articles (8 Total)